Oseltamivir phosphate
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1999
- First approval year
- 1999
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Oseltamivir phosphate
- Molecular weight
- 410.4
- Structure (SMILES)
- CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1.O=P(O)(O)O
- ebilfumin
- Ebilfumin
- oseltamivir phosphate
- Oseltamivir phosphate
- tamiflu
- Tamiflu
- (-)-Oseltamivir phosphate
- (3R-(3.ALPHA.,4.BETA.,5.ALPHA.))-ETHYL 4-(ACETYLAMINO)-5-AMINO-3-(1-ETHYLPROPOXY)-1-CYCLOHEXENE-1-CARBOXYLATE PHOSPHATE (1:1)
- 3r 3 alpha 4 beta 5 alpha ethyl 4 acetylamino 5 amino 3 1 ethylpropoxy 1 cyclohexene 1 carboxylate phosphate 1 1
- agucort
- Agucort
- Oseltamivir (as phosphate)
- oseltamivir as phosphate
- oseltamivir phosphate
- Oseltamivir phosphate
- Oseltamivir phosphate [EP MONOGRAPH]
- Oseltamivir phosphate [JAN]
- Oseltamivir phosphate [MART.]
- Oseltamivir phosphate [MI]
- Oseltamivir phosphate [ORANGE BOOK]
- Oseltamivir phosphate [USAN]
- Oseltamivir phosphate [USP IMPURITY]
- Oseltamivir phosphate [USP MONOGRAPH]
- Oseltamivir phosphate [USP-RS]
- Oseltamivir phosphate [VANDF]
- Oseltamivir phosphate [WHO-DD]
- Oseltamivir phosphate [WHO-IP]
- oseltamivir phosphate ep monograph
- oseltamivir phosphate jan
- oseltamivir phosphate mart
- oseltamivir phosphate mi
And 22 more, listed on the interactive page.
- CAS registry numbers
- 204255-11-8
- ChEMBL ID
- CHEMBL1200340
- InChIKey
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N
- RxNorm IDs (RxCUI)
- 259275
- FDA ingredient codes (UNII)
- 4A3O49NGEZ
- 78000
- 11154112
- Applicant
- ROCHE
- Approval date
- 27 Oct 1999
- Application number
- NDA021087
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Drug name stem
- -vir
Administration routes
- Oral
- Mechanism
- Neuraminidase inhibitor
- Action type
- Inhibitor
- Target
- Neuraminidase
- Protein identifier
- P03468
- Mechanism
- Neuraminidase inhibitor
- Action type
- Inhibitor
- Target
- Neuraminidase
- Protein identifier
- P03474
Open Targets mechanisms
- Mechanism
- Neuraminidase inhibitor
- Action type
- Inhibitor
- Target
- Neuraminidase
- Condition
- Virus Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000763
- Subject identifier
- D014777
- Condition
- Kidney Failure, Chronic
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003884
- Subject identifier
- D007676
- Condition
- Influenza, Human
- Highest recorded phase
- 4
- Condition identifier
- EFO:0007328
- Subject identifier
- D007251
- Condition identifier
- EFO_0003884
- Condition identifier
- EFO_0007328
- Condition identifier
- MONDO_0005300
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005812
- Highest recorded phase
- 4
- Event
- abnormal behaviour
- Reports
- 690
- Reporting signal score
- 1,934.97
- Event
- convulsion
- Reports
- 158
- Reporting signal score
- 117.806
- Event
- delirium
- Reports
- 199
- Reporting signal score
- 287.141
- Event
- enterocolitis haemorrhagic
- Reports
- 43
- Reporting signal score
- 116.701
- Event
- fatigue
- Reports
- 56
- Reporting signal score
- 119.781
- Event
- hallucination
- Reports
- 307
- Reporting signal score
- 451.452
- Event
- influenza
- Reports
- 196
- Reporting signal score
- 181.444
- Event
- injection site pain
- Reports
- 1
- Reporting signal score
- 86.5281
- Event
- normal newborn
- Reports
- 331
- Reporting signal score
- 1,233.88
- Event
- pregnancy
- Reports
- 274
- Reporting signal score
- 565.467
- Event
- premature delivery
- Reports
- 72
- Reporting signal score
- 86.0895
- Event
- vomiting
- Reports
- 442
- Reporting signal score
- 122.371
- NCT00803595
- NCT00979251
- NCT00988325
- NCT01053377
- NCT01053663
- NCT01690637
- NCT02232945
- NCT02572583
- NCT02662426
- NCT02989012
- NCT02469298
- Dose
- 75 mg
- Route
- Oral
- How often
- Twice daily for 5 days
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 2
- Polar surface area
- 90.65
- Calculated partition coefficient (ALogP)
- 1.29
- Prodrug
- Yes
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 7
- Heavy atoms
- 27
- Molecular formula
- C16H31N2O8P
- Monoisotopic mass
- 410.18180295
- Natural product
- No
- 0004-0800
- 0004-0802
- 0004-0822
- 0093-8180
- 0527-4591
- 0527-4592
- 0527-4593
- 0527-5137
- 27241-139
- 31722-108
- 31722-630
- 31722-631
- 31722-632
- 33342-256
- 33342-257
- 33342-258
- 42291-567
- 42291-664
- 42291-666
- 42385-985
- 42385-986
- 42385-987
- 42677-320
- 42677-321
- 42677-322
And 101 more, listed on the interactive page.
- Recorded assays
- 166
- Active assays
- 20
Active assay types
- Confirmatory
- Antiviral Agents
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
- Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
Oral bioavailability
- Median
- 4.3
- Mean
- 4.3
- Minimum
- 4.3
- Maximum
- 4.3
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (138)
- A Bioequivalence Study of Oseltamivir From Oseltamivir 75 mg Caps (Pharmacare PLC, Palestine) and Tamiflu® 75 mg Caps (Hoffmann-La Roche, Switzerland)
- A Clinical Study of Treating Influenza With Liugan Shuangjie Heji
- A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection
- A Clinical Trial to Investigate the Influence of CES1 Polymorphism on Oseltamivir
- A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872
- A Multicenter Randomized Open-label Study of Oseltamivir Combined With HD-DEX Versus HD-DEX in the Management of ITP
- A Multinational Phase III Study of CS-8958 (MARVEL)
- A Multiple-Dose Study of Oral Oseltamivir in Participants on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD)
- A Pharmacokinetic Study on Co-administration of Tamiflu (Oseltamivir) and Rimantadine in Healthy Volunteers
- A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu Infection
- A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection
- A Pharmacokinetics Study of Favipiravir in Patients With Severe Influenza
- A Pharmacokinetics, Pharmacodynamics and Safety Study of Warfarin in Combination With Tamiflu (Oseltamivir)
- A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza
- A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza
- A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia
- A Randomised Controlled Trial on the Effect of Post-exposure Oseltamivir Prophylaxis on Influenza Transmission in Nursing Homes
- A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia
- A Single Dose Study of Tamiflu in Volunteers in Dialysis And in Volunteers With Reduced Creatinine Clearance
- A Study of Intravenous Oseltamivir [Tamiflu] in Infants With Influenza
Approved for (2)
In development for (1)
- Viral infectious disease Phase 2